Capsid and Reverse Transcriptase Inhibitor Combination for HBV Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B virus infection, such as nucleos(t)ide compounds and interferons, are inadequate in effectively addressing the replication and diversity of the hepatitis B virus, necessitating the development of more potent therapeutic agents.
Innovation Solution
A pharmaceutical combination of a capsid protein inhibitor and a reverse transcriptase inhibitor, specifically compounds like entecavir or tenofovir, is administered to target the nucleocapsid assembly and inhibit HBV replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (nucleos(t)ide compounds and interferons) are used to treat hepatitis B virus infection, then treatment options are available, but therapeutic efficacy is insufficient to effectively address HBV replication and diversity
Solution Approach 1:
The patent combines a capsid protein inhibitor (which targets nucleocapsid assembly) with a reverse transcriptase inhibitor (such as entecavir or tenofovir) to create a pharmaceutical composition with synergistic antiviral activity. This combination approach addresses both the replication process and viral diversity, overcoming the limitations of single-agent therapies by targeting multiple stages of the HBV life cycle simultaneously
Solution Approach 2:
The treatment strategy is divided into two distinct functional components: a capsid protein inhibitor that interferes with nucleocapsid formation and assembly, and a reverse transcriptase inhibitor that blocks viral DNA synthesis. By segmenting the therapeutic approach into these two mechanisms of action, the patent achieves more comprehensive coverage of HBV replication pathways and improves overall therapeutic efficacy
2Reliability
If a capsid protein inhibitor is combined with a reverse transcriptase inhibitor, then therapeutic efficacy is significantly enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges two antiviral agents with complementary mechanisms of action into a single pharmaceutical composition or coordinated treatment regimen. By combining the capsid protein inhibitor and reverse transcriptase inhibitor in one formulation or treatment protocol, the patent enhances therapeutic efficacy while managing complexity through integrated delivery and coordinated administration
Data Source
AI summary
The present invention belongs to the field of medicinal chemistry, and relates to a pharmaceutical combination containing a capsid protein inhibitor or a pharmaceutically acceptable salt thereof and a reverse transcriptase inhibitor or a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt or a solvate thereof. Specifically, the present invention relates to a pharmaceutical combination of a capsid protein inhibitor or a pharmaceutically acceptable salt thereof and entecavir or tenofovir, or a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt or a solvate thereof, or the use thereof in the treatment of hepatitis B virus infection. The pharmaceutical combination has a good anti-hepatitis B virus infection effect.